To investigate possible regulatory mechanisms of UGN expression in the brain, we selected insulin and GLP-1 (liraglutide) because both hormones can activate BAT shortly after a meal and are used in the treatment of patients with T2D (Lockie et al., 2012; Benedict et al., 2011). The gene discussed is INS; the disease is type 2 diabetes mellitus.